I know only the facts I reported re NVS from a PR alert I read. Entry of the MSN generic into the market may occur because the Delaware District Court judge did opine that the MSN product does NOT infringe the claims of the NVS patent. That early entry is not risk-free. E.g., I'ts possible NVS could obtain a reversal of the D.Ct. judgment/decision from CAFC prior to Entresto patent expiration in November 2026.
Market Data 
Markets 
